Trial Profile

A Phase 1b/2, Open-Label, Multicenter Study of Mavorixafor in Patients With Congenital Neutropenia and Chronic Neutropenia Disorders

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavorixafor (Primary) ; Granulocyte colony stimulating factor inhibitors
Indications Neutropenia
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors X4 Pharmaceuticals

16 Jun 2025 According to X4 Pharmaceuticals media release, company presented result data from phase 2 portion at the 30th Annual Congress of the European Hematology Association (EHA) in Milan, Italy.
16 Jun 2025 Results (n=23) from the phase 2 portion presented in the X4 Pharmaceuticals Media Release.
14 May 2025 According to X4 Pharmaceuticals media release, company announced data from this study will be presented as a poster presentation at the 30th Annual Congress of the European Hematology Association (EHA) taking place in Milan, Italy on Thursday, June 12.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com